TransMedics Group: Strong Long-Term Investment Despite Short-Term Sales Fluctuations

William Blair analyst Ryan Daniels has maintained their bullish stance on TMDX stock, giving a Buy rating on September 26.

Ryan Daniels’s rating is based on a combination of factors that suggest TransMedics Group, despite a potential shortfall in third-quarter sales estimates, remains a strong investment. The anticipated decline in sales is attributed to seasonal fluctuations in transplant volumes, which is a common occurrence in the industry. Daniels projects third-quarter revenue to be around $140 million, slightly below the consensus estimate of $145.3 million, but still within a reasonable range considering the seasonal trends.
Despite the short-term adjustments, Daniels maintains a positive outlook for TransMedics Group, with projections indicating that the company’s revenue for 2025 will reach $597.7 million. This figure, while slightly below full-year Street expectations, is above the midpoint of management’s guidance, suggesting a solid long-term growth trajectory. The analysis of flight volumes, which showed a rebound in September, further supports the view that the company is well-positioned to capitalize on future opportunities, justifying the Buy rating.

Daniels covers the Healthcare sector, focusing on stocks such as TransMedics Group, Addus Homecare, and Healthcare Services. According to TipRanks, Daniels has an average return of 9.0% and a 53.90% success rate on recommended stocks.

In another report released on September 26, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $131.00 price target.